

Date: 26 February 2021

Re: Freedom of Information Request
Ref: 37-2021

Thank you for your email dated the 3rd February 2021, requesting information in relation to patient treatment figures.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

- 1. How many patients are currently (in the past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+?**
301 patients of which are currently (in the past 3 months) undergoing treatment for melanoma:
 - 85 BRAF positive
 - 69 BRAF Negative
 - 47 Awaiting Assessment
- 2. In the past 3 months, how many melanoma patients (any stage) were treated with the following:**

• Cobimetinib	0
• Dabrafenib	Exempt under S.40
• Dabrafenib AND Trametinib	35
• Encorafenib AND Binimetinib	0

• Ipilimumab	Exempt under S.40
• Ipilimumab AND Nivolumab	21
• Nivolumab	32
• Pembrolizumab	109
• Trametinib	0
• Vemurafenib	0
• Vemurafenib AND Cobimetinib	0
• Other active systemic anti-cancer therapy	10
• Palliative care only*	Exempt under S.40

*Had a palliative care appointment with CCC but no active treatment. This does not take into account patients who may be involved with community palliative care.

3. If possible, could you please provide the patients treated in the past 3 months with the following therapies for metastatic melanoma ONLY:

Please note, we only record stage at presentation to CCC , therefore the data provided below is based on the number of patients who presented with stage IV disease or recurrence/progression

Between 1st Nov 2020-31st Jan 2021

• Ipilimumab	Exempt under S.40
• Ipilimumab AND Nivolumab	14
• Nivolumab	Exempt under S.40
• Pembrolizumab	32
• Any other therapies	7

4. In the past 3 months how many patients were treated with the following for breast cancer?

• Abemaciclib + Anastrozole/Exemestane/Letrozole	0
• Abemaciclib + Fulvestrant	17
• Alpelisib + Fulvestrant	0
• Atezolizumab	Exempt under S.40
• Bevacizumab	0
• Eribulin	17
• Everolimus + Exemestane	0
• Fulvestrant as a single agent	0
• Gemcitabine + Paclitaxel	0
• Lapatinib	0
• Neratinib	35
• Olaparib	0
• Palbociclib + Anastrozole/Exemestane/Letrozole	0
• Palbociclib + Fulvestrant	30
• Pertuzumab + Trastuzumab + Docetaxel	12
• Ribociclib + Anastrozole/Exemestane/Letrozole	0
• Ribociclib + Fulvestrant	Exempt under S.40
• Talazoparib	Exempt under S.40
• Transtuzumab + Paclitaxel	0
• Transtuzumab as a single agent	178
• Trastuzumab emtansine (Kadcyla)	65
• Any other active systemic anti-cancer therapy	1178

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be

addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>